Tetanus Toxoid
Giant Cell Glioblastoma
Mustafa Khasraw, MBChB, MD, FRCP, FRACPvaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Giant Cell Glioblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rindopepimut Celldex Therapeutics | Phase 3 | BB |
Keyhole Limpet Hemocyanin Celldex Therapeutics | Phase 3 | BB |
Gm-Csf Celldex Therapeutics | Phase 3 | BB |
Dcs Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Phase 2 | B |
Basiliximab Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Phase 2 | B |
View all 30 →
Same molecule, other indications
Tetanus Toxoid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →